Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea

Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea

Abstract Background Anti-PD1 inhibitors have been approved for the treatment of recurrent or metastatic head and neck cancer (HNC), as a result of Global Phase III trials. However, the clinical outcomes of immune checkpoint inhibitors in patients who are not eligible for clinical trials or have vari...

Full description

Bibliographic Details
Main Authors: Hyera Kim, Minsuk Kwon, Binnari Kim, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Keunchil Park, Myung-Ju Ahn
Format: Article
Language:English
Published: BMC 2020-08-01
Series:BMC Cancer
Subjects:
Immune checkpoint inhibitor
Head and neck cancer
Pembrolizumab
Nivolumab
Online Access:http://link.springer.com/article/10.1186/s12885-020-07214-4

Internet

http://link.springer.com/article/10.1186/s12885-020-07214-4

Similar Items